Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nicovape Q
- Development stage
- Unknown
- Lead developer
- Liber Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Nicovape Q is an inhaled nicotine replacement therapy (iNRT) developed by Liber Pharmaceuticals. It is a closed-system nicotine liquid inhaler designed to deliver nicotine to the lungs via inhalation, providing a pharmacokinetic profile that more closely mimics the rapid nicotine delivery of combustible cigarettes compared to traditional nicotine replacement therapies (NRTs) such as patches or gums. The device aerosolizes a nicotine-containing solution which, upon inhalation, activates nicotinic acetylcholine receptors (nAChRs) in the central nervous system to alleviate cravings and withdrawal symptoms associated with smoking cessation. In September 2021, Nicovape Q became the first nicotine vaping product to be registered on the Australian Register of Therapeutic Goods (ARTG) as a prescription-only medicine for smoking cessation.
- Brand names
- Nicovape Q
- Other names
- NicovaperNicovape Q-Nicovaperinhaled nicotine replacement therapyiNRTnicotine-containing liquid inhaler
02
Targets
α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)CHRNA2 (nAChR α2)CHRNA7 (α7 nicotinic receptor)
Beyond the preview
Go deeper on Nicovape Q.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nicovape Q.